Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?-Reference-Cited by-同舟云学术

Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?

Published:2020-08-24 Issue:9 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Shafeque Arena¹,Bigio Jacob²³,Hogan Catherine A.¹⁴,Pai Madhukar³⁵,Banaei Niaz¹⁴⁶

Affiliation:

1. Department of Pathology, Stanford University School of Medicine, Stanford, California, USA

2. Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

3. McGill International TB Centre, Montreal, Quebec, Canada

4. Clinical Microbiology Laboratory, Stanford Health Care, Stanford, California, USA

5. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

6. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA

Abstract

QuantiFERON-TB Gold Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive approval from the U.S. FDA, replacing its predecessor, QuantiFERON-TB Gold In-Tube (QFT-GIT). The novelty of QFT-Plus is that it elicits a response from CD8 T cells, in addition to CD4 T cells, thus collecting a broader response from T-cell subsets than QFT-GIT. It was developed with the aim to improve the detection of latent tuberculosis infection (LTBI), especially among recently exposed contacts, immunocompromised hosts, and young children.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01950-19

Reference34 articles.

1. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling

2. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection

3. Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?

4. Mycobacterium tuberculosis-specific CD8+T cells are functionally and phenotypically different between latent infection and active disease

5. Patients with Tuberculosis Disease Have Mycobacterium tuberculosis-Specific CD8 T Cells with a Pro-Apoptotic Phenotype and Impaired Proliferative Capacity, Which Is Not Restored following Treatment

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers;PLOS ONE;2024-05-10

2. Cost-Effectiveness Analysis Comparing QuantiFERON-TB Gold Plus Test and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompetent Subjects in Colombia;Value in Health Regional Issues;2024-05

3. A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection;Clinical Chemistry;2024-02-01

4. Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study;BMC Infectious Diseases;2024-01-02

5. Interferon-Gamma Release Assay Combined with Renal Indicators to Reduce the False-Negativity of Latent Tuberculosis Infection in End-Stage Renal Disease with Hemodialysis Patients;Discovery Medicine;2024